Xudong Wu
a State Key Laboratory of Experimental Hematology, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Cancer Institute and Hospital, Department of Cell Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China;
b Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin 300052, China
Funds: We thank members of the Wu laboratory for discussions. This work was supported by the National Key Research and Development Program (2017YFA0504102), the National Natural Science Foundation of China (81772676, 31970579), and the Natural Science Foundation of Tianjin Municipal Science and Technology Commission (18JCJQJC48200), Key Research Project of Tianjin Education Commission (2020ZD13), Open grant from the Chinese Academy of Medical Sciences (157-Zk19-02 and Z20-04) and the Talent Excellence Program from Tianjin Medical University and Research Project of Tianjin Education Commission.
Received Date: 2021-01-20
Accepted Date:2021-03-28
Rev Recd Date:2021-03-23
Publish Date:2021-06-20
Abstract
Abstract
The Polycomb group (PcG) proteins are a family of chromatin regulators and critical for the maintenance of cellular identity. The PcG machinery can be categorized into at least three multi-protein complexes, namely Polycomb Repressive Complex 1 (PRC1), PRC2, and Polycomb Repressive DeUBiquitinase (PR-DUB). Their deregulation has been associated with human cancer initiation and progression. Here we review the updated understanding for PcG proteins in transcription regulation and DNA damage repair and highlight increasing links to the hallmarks in cancer. Accordingly, we discuss some of the recent advances in drug development or strategies against cancers caused by the gain or loss of PcG functions.Keywords: Polycomb group,
Polycomb repressive complex,
Cancer,
Epigenetic,
Transcription regulation
PDF全文下载地址:
http://www.jgenetgenomics.org/article/exportPdf?id=83e9e23e-9532-49ad-b9b0-dba46ebd4eeb&language=en
